In our study, the utilization of cell surface proteomics to validate EphA3 as a target for glioma treatment has showcased its effectiveness in detecting promising immunotherapy biomarkers and targets directly from fresh primary brain tumors. This evidence concerns the gene EPHA3 and brain neoplasm.